Adalvo announces the launch of the first-ever generic version of Nitrofurantoin to the UK, in collaboration with CNX Therapeutics. Having developed this product in-house, Adalvo are very proud to bring 1st generic of Nitrofurantoin ER to UK market, even though the patent has expired in 2007.
“Nitrofurantoin is a unique and challenging product,” said Anil Okay, CEO of Adalvo. “This launch highlights Adalvo’s ability to navigate complex development and regulatory pathways while also delivering high-quality differentiated treatments to market. We are excited to bring this product to the UK market and remain dedicated to expanding access to high-quality treatments.”
The introduction of Nitrofurantoin as the first generic version in the UK ensures that healthcare providers now have access to a high-quality therapeutic alternative.
“We are very excited to be partnering with Adalvo to launch a prolonged release formulation of Nitrofurantoin in Europe”, said Guy Clark, CEO of CNX Therapeutics. “This partnership aligns with CNX’s strategy to provide innovative, high-quality products that meet the needs of healthcare providers to transform patient care. Our partnership with Adalvo has been key in bringing this important product to market, and we look forward to continuing our collaboration to expand access to essential medicines.”
This unique launch reinforces Adalvo’s position as a leader in bringing complex and differentiated products to market while also demonstrating the strength of our collaborative approach to achieving shared success.
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 19 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customised to our partners, and designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help our partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.
The company’s purpose-driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About CNX
CNX Therapeutics is a speciality pharmaceutical company committed to improving the lives of patients by providing access to essential medicines. CNX commercialises and distributes a portfolio of pharmaceuticals for neurological, psychiatric and hospital emergencies in over 60 markets worldwide, both directly and through strategic partnerships, and is an attractive partner for companies who are looking for a pan-European partner for Central Nervous System (CNS) and hospital injectable products, which is committed to the highest standards of ethics and sustainability. For more information, visit: www.cnx-therapeutics.com